Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

The firm will evaluate VS-7375 as both monotherapy and in combination with Eli Lilly's EGFR inhibitor Erbitux in the study.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS- ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

Researchers have identified a mutation in a common oncogene that may play an important role in colon cancer. Their findings ...

A new study [1] from the Medical University of Vienna has uncovered a surprising vulnerability in colorectal cancers driven ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the ...

Despite a robust cash position, Revolution Medicines' high burn rate and lofty valuation increase risk and sensitivity to ...

Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus ...